MYO10 regulates genome stability and cancer inflammation through mediating mitosis
Franklin Mayca Pozo,
Xinran Geng,
Masaru Miyagi,
Amanda L. Amin,
Alex Y. Huang,
Youwei Zhang
Affiliations
Franklin Mayca Pozo
Department of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA; Corresponding author
Xinran Geng
Department of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA
Masaru Miyagi
Department of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA
Amanda L. Amin
Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA
Alex Y. Huang
Center for Pediatric Immunotherapy at Rainbow, Angie Fowler AYA Cancer Institute, University Hospitals, Cleveland, OH 44106, USA; Division of Pediatric Hematology/Oncology, University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH 44106, USA; Department of Pediatrics, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA
Youwei Zhang
Department of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA; Corresponding author
Summary: Genomic instability can promote inflammation and tumor development. Previous research revealed an unexpected layer of regulation of genomic instability by a cytoplasmic protein MYO10; however, the underlying mechanism remained unclear. Here, we report a protein stability-mediated mitotic regulation of MYO10 in controlling genome stability. We characterized a degron motif and phosphorylation residues in the degron that mediate β-TrCP1-dependent MYO10 degradation. The level of phosphorylated MYO10 protein transiently increases during mitosis, which is accompanied by a spatiotemporal cellular localization change first accumulating at the centrosome then at the midbody. Depletion of MYO10 or expression of MYO10 degron mutants, including those found in cancer patients, disrupts mitosis, increases genomic instability and inflammation, and promotes tumor growth; however, they also increase the sensitivity of cancer cells to Taxol. Our studies demonstrate a critical role of MYO10 in mitosis progression, through which it regulates genome stability, cancer growth, and cellular response to mitotic toxins.
